From MedPageToday.com
MS: Slow Progression With Vitamin D?
Jan 20, 2014
By John Gever, Deputy Managing Editor, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
Patients with relatively high vitamin D levels in the year after a first multiple sclerosis-like attack showed, over the next 4 years, markedly lower levels of MS disease activity and disability progression than those with lower levels, researchers found.
Each 20 ng/mL increment in serum levels of 25-hydroxyvitamin D (25-OH-D), the active metabolite of vitamin D, averaged during the first 12 months of participation in a clinical trial of interferon-beta (Betaseron) was associated with nearly 60% lower rates of new MRI lesions and clinical relapses, (both P'<'0.05) during subsequent follow-up relative to those with smaller or noincreases in 25-OH-D levels, according to Alberto Ascherio, MD, DrPH, of Harvard School of Public Health, and colleagues.
Continue reading at MedPageToday.com >>MS: Slow Progression With Vitamin D?
Jan 20, 2014
By John Gever, Deputy Managing Editor, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
Patients with relatively high vitamin D levels in the year after a first multiple sclerosis-like attack showed, over the next 4 years, markedly lower levels of MS disease activity and disability progression than those with lower levels, researchers found.
Each 20 ng/mL increment in serum levels of 25-hydroxyvitamin D (25-OH-D), the active metabolite of vitamin D, averaged during the first 12 months of participation in a clinical trial of interferon-beta (Betaseron) was associated with nearly 60% lower rates of new MRI lesions and clinical relapses, (both P'<'0.05) during subsequent follow-up relative to those with smaller or noincreases in 25-OH-D levels, according to Alberto Ascherio, MD, DrPH, of Harvard School of Public Health, and colleagues.
No comments:
Post a Comment